ClinicalTrials.Veeva

Menu
F

Florida Eye Associates | Melbourne, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ranibizumab
KSI-301
Lampalizumab
Aflibercept
KHK4951
Faricimab
Zimura
AGN-190584
BI 771716
Avacincaptad pegol

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 40 total trials

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment

Enrolling
Neovascular (Wet) Age-Related Macular Degeneration
Biological: Aflibercept IVT
Biological: 4D-150 IVT

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.

Enrolling
Non-proliferative Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection

This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intr...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Other: Sham Procedure
Drug: Faricimab

Study BP43464 is a phase II, multicenter, randomized, double-masked active comparator-controlled study designed to assess the efficacy, safety, toler...

Active, not recruiting
Diabetic Macular Edema
Drug: Vamikibart
Drug: Ranibizumab

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Enrolling
Macular Edema Secondary to Retinal Vein Occlusion
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg
Drug: Sham

The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Ed...

Enrolling
Edema
Diabetic Macular Edema
Drug: foselutoclax
Drug: Aflibercept

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting
Age-Related Macular Degeneration
Geographic Atrophy
Drug: avacincaptad pegol

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in patients with neovas...

Enrolling
Neovascular Age-Related Macular Degeneration
Drug: PDS Implant with Ranibizumab 100 mg/mL

The purpose of this Phase 1 study is comprised of multiple ascending-dose component (Part 1) and high concentration component (Part 2) to evaluate th...

Enrolling
Neovascular Age-related Macular Degeneration
Biological: AM712(ASKG712)

In this study researchers want to learn more about changes in visual acuity (clarity of vision) with a high dose treatment with Aflibercept (Eylea) i...

Active, not recruiting
Neovascular Age-Related Macular Degeneration
Drug: Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Drug: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.

Enrolling
Diabetic Macular Edema (DME)
Drug: KHK4951
Drug: Aflibercept Injection

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

Enrolling
Neovascular Age-Related Macular Degeneration (nAMD)
Drug: Aflibercept Injection
Drug: KHK4951

Trial sponsors

Roche logo
Kodiak Sciences logo
Genentech logo
Bayer logo
Kyowa Kirin logo
4
A
Allergan logo
Astellas logo
Boehringer Ingelheim logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems